SCHEMBL7205312

SCHEMBL7205312

COc1ccc(COc2ccc(S(=O)(=O)C3CCN(C(N)=O)CC3(O)C(=O)O)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 7/20 0.47
MMP13 P45452 6/20 0.47
ADAMTS4 O75173 4/20 0.45
HRH3 Q9Y5N1 1/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 2/20 0.41
POLB P06746 2/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
PKM P14618 1/20 0.39
HTT P42858 1/20 0.39
TSHR P16473 1/20 0.39
FFAR1 O14842 1/20 0.39
MMP2 P08253 1/20 0.39
MMP7 P09237 1/20 0.39
MMP9 P14780 1/20 0.39
MMP12 P39900 1/20 0.39
MMP14 P50281 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7205273 0.93 MMP1 (0.56) MMP1MMP13ADAMTS4HRH3ALDH1A1
SCHEMBL7203984 0.92 MMP1 (0.45) MMP1MMP13ADAMTS4RAB9ANPC1
SCHEMBL7205420 0.91 MMP1 (0.45) MMP1MMP13ADAMTS4HRH3MMP2
SCHEMBL7205347 0.91 MMP1 (0.56) MMP1MMP13ADAMTS4HRH3RAB9A
SCHEMBL7201220 0.90 MMP1 (0.47) MMP1MMP13SMN1; SMN2RAB9ANPC1
SCHEMBL7202584 0.89 RORC (0.46) MMP1MMP13ADAMTS4MMP2MMP9
SCHEMBL7205455 0.88 MMP9 (0.44) MMP1MMP13SMN1; SMN2POLBALDH1A1
SCHEMBL7203058 0.88 MMP9 (0.47) MMP1MMP13SMN1; SMN2POLBALDH1A1
SCHEMBL7201575 0.86 MMP13 (0.43) MMP1MMP13ADAMTS4MMP2
SCHEMBL7201801 0.86 MMP1 (0.57) MMP1MMP13ADAMTS4FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP1 8/4885MMP13 4/4885ADAMTS4 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.